Immunohistochemistry (IHC) Applications

Faculty of Pharmacy

Tishk International University

Lecture 12.

By

Dr. Ahmad H. Ibrahim

2024

Immunohistochemistry (IHC) Applications

This lecture provides an overview of immunohistochemistry, its historical development, applications, sample preparation, antibody types, detection methods, troubleshooting, diagnostic markers, therapy direction, and protein expression mapping.

I. Introduction

- **A. Overview of Immunohistochemistry (IHC)**
  - **Definition and purpose**
  - **Historical development**
- **B. Importance in Clinical Pathology and Research**
  - **Role in diagnosing diseases**
  - **Impact on treatment decisions**

II. Principles of Immunohistochemistry

- **A. Antigen-Antibody Interactions**
  - **Basic concepts of antigen and antibody binding**
  - **Types of antibodies used (monoclonal vs. polyclonal)**
- **B. Detection Systems**
  - **Enzyme-linked detection (e.g., HRP, AP)**
  - **Fluorescent detection methods**

III. Application in Diagnosis

- **A. Diagnosing Cancerous Tumors**
    - **Identifying abnormal cells**
    - **Differentiating tumor types**
- **B. Clinical Examples**
    - **Use in breast cancer (e.g., ER, PR, HER2 testing)**
    - **Use in gastrointestinal stromal tumors (KIT)**

IV. Sample Preparation Techniques

- **A. Tissue Fixation**
    - **Purpose and methods (e.g., formalin fixation)**
- **B. Antigen Retrieval**
    - **Importance and techniques (e.g., heat-induced, enzymatic)**
- **C. Antibody Labeling**
    - **Primary and secondary antibody application**
    - **Blocking non-specific binding**

V. Troubleshooting and Optimization

- **A. Common Issues**
    - **Background staining**
    - **Weak target antigen staining**
- **B. Strategies for Improvement**
    - **Optimizing antigen retrieval**
    - **Adjusting antibody concentrations**
    - **Enhancing detection sensitivity**

VI. Clinical Relevance

- **A. Directing Therapy in Cancer Treatment**

- **Assessing molecular targets**
- **Role in personalized medicine**

- **B. Case Studies**
  - **Tamoxifen in hormone receptor-positive breast cancer**
  - **Imatinib in chronic myelogenous leukemia and GIST**
  - **Monoclonal antibodies (Herceptin, Erbitux)**

VII. Future Directions in Immunohistochemistry

- **A. Advances in Techniques**
  - **Multiplex IHC**
  - **Digital pathology and AI analysis**
- **B. Expanding Clinical Applications**
  - **Emerging biomarkers and targets**
  - **Integration with other diagnostic tools**

VIII. Conclusion

- **A. Summary of Key Points**
  - **Recap of principles, applications, and clinical relevance**
- **B. Q&A Session**
  - **Addressing student questions and clarifications**

IX. References and Further Reading

- **List of recommended articles and textbooks for deeper understanding**

This outline provides a comprehensive structure for a lecture on Immunohistochemistry, covering foundational concepts, practical applications, technical details, and clinical implications.

Lecture Outcomes for Immunohistochemistry (IHC)

These outcomes will ensure that students have a thorough understanding of the principles, applications, and clinical significance of immunohistochemistry, enabling them to effectively apply this knowledge in both research and clinical practice. the following outcomes should be achieved by the end of the lecture on Immunohistochemistry (IHC):

1. **Understanding the Principles of Immunohistochemistry:**
    - **Students will be able to explain the basic principles of immunohistochemistry, including how antigen-antibody interactions form the foundation of the technique.**
    - **Students will understand the historical development of immunohistochemistry and its evolution into a crucial tool in pathology and research.**
2. **Application in Diagnosis:**
    - **Students will be able to discuss how immunohistochemistry is used to diagnose abnormal cells, with a focus on cancerous tumors.**
    - **Students will recognize the importance of immunohistochemistry in clinical pathology and its role in differentiating between different types of tumors based on protein expression.**
3. **Sample Preparation Techniques:**
    - **Students will outline the detailed steps involved in preparing tissue samples for immunohistochemical analysis, including the processes of tissue fixation, antigen retrieval, and labeling with specific antibodies.**
    - **Students will understand the importance of each step in ensuring accurate and reliable immunohistochemical results.**
4. **Troubleshooting and Optimization:**
    - **Students will identify common problems encountered in immunohistochemistry, such as non-specific background staining or weak staining of the target antigen.**
    - **Students will discuss various strategies for troubleshooting these issues, including optimizing antigen retrieval methods, adjusting antibody concentrations, and improving detection techniques.**
5. **Clinical Relevance:**

- **Students will be able to highlight the clinical relevance of immunohistochemistry in guiding cancer therapy by identifying molecular targets such as hormone receptors and tyrosine kinases.**
- **Students will understand how immunohistochemical findings can influence treatment decisions, including the selection of targeted therapies such as antiestrogens, tyrosine kinase inhibitors, and monoclonal antibodies.**

Objectives for the Lecture on Immunohistochemistry (IHC):

1. **Understanding the Principles: Explain the underlying principles of immunohistochemistry, including the concept of antigen-antibody interactions and the development of the technique over time.**
2. **Application in Diagnosis: Discuss the role of immunohistochemistry in diagnosing abnormal cells, particularly cancerous tumors, and its significance in clinical pathology.**
3. **Sample Preparation Techniques: Outline the steps involved in preparing tissue samples for immunohistochemical analysis, including fixation, antigen retrieval, and labeling with specific antibodies.**
4. **Troubleshooting and Optimization: Identify common issues encountered during immunohistochemistry, such as background staining and weak target antigen staining, and discuss strategies for troubleshooting and optimizing the technique.**
5. **Clinical Relevance: Highlight the clinical relevance of immunohistochemistry in directing therapy, particularly in cancer treatment, by assessing molecular targets and guiding the selection of targeted therapies.**

Introduction:

- **Immunohistochemistry (IHC) is a technique used to identify antigens (proteins) in cells and tissues.**
- **It involves exploiting antibodies' specific binding to antigens in biological tissues.**

Application:

- **Widely used in diagnosing abnormal cells, especially cancerous tumors.**

- **Essential in basic research to understand biomarker distribution and protein expression in biological tissues.**

Sample Preparation:

- **Can be performed on fixed and paraffin-embedded or frozen tissue.**
- **Steps include fixation, antigen retrieval, primary antibody incubation, and secondary antibody incubation.**

Antigen Retrieval:

- **Necessary to make epitopes accessible due to masking during fixation.**
- **Commonly performed using heat-induced epitope retrieval methods.**

Blocking:

- **Reduces nonspecific antibody binding and background staining.**
- **Utilizes normal serum or commercially available blocking buffers.**

Sample Labeling:

- **Visualization of target using fluorescent compounds, metals, or enzymes.**
- **Direct and indirect labeling methods are employed.**

Antibody Types:

- **Polyclonal antibodies: Isolated from animals and recognize multiple epitopes.**
- **Monoclonal antibodies: Show specificity for a single epitope.**



Detection Methods:

- **Direct method: Utilizes a labeled antibody directly reacting with the antigen.**



- **Indirect method: Employs unlabeled primary antibody and labeled secondary antibody for signal amplification.**

Reporter Molecules:

- **Chromogenic detection: Enzyme-conjugated antibodies catalyze a color-producing reaction.**
- **Fluorescent detection: Antibodies tagged with fluorophores for visualization.**



Cytokeratin for identifying intermediate trophoblasts in the placenta. (**a**): H&E, (**b**): cytokeratin immunostaining. Intermediate trophoblasts (arrows) are observed in the stroma of the placental tissue sampled by curettage. Cytokeratin immunoreactivity with a monoclonal antibody CAM5.2 clearly illustrates their distribution.

Counterstains:

- **Applied after immunohistochemical staining to provide contrast and aid in tissue examination.**
- **Hematoxylin is commonly used.**

Troubleshooting:

- **Addresses issues like background staining, weak target antigen staining, and presence of artifacts.**
- **Optimizing antibody quality and techniques are crucial.**

Diagnostic IHC Markers:

- **Used in surgical pathology for tumor immunophenotyping and differential diagnoses.**
- **Examples include BrdU, cytokeratins, CD markers, and hormone receptors.**

Directing Therapy:

- **Identifies molecular targets altered in cancer for targeted therapy.**
- **Assesses the presence or elevated levels of molecular targets using IHC.**

Chemical Inhibitors:

- **Hormone receptors and intracellular targets detected by IHC guide therapy selection.**
- **Examples include antiestrogens and tyrosine kinase inhibitors.**

Monoclonal Antibodies:

- **Target proteins upregulated in pathological states for therapeutic monoclonal antibody use.**
- **Examples include Herceptin for HER2/neu overexpression in breast cancer.**

Mapping Protein Expression:

- **Used for protein profiling in normal organs, tissues, and cancers.**
- **Combined with tissue microarrays, it provides comprehensive protein expression patterns.**

References

Buchwalow, I.B. and Böcker, W., 2010. ***Immunohistochemistry: basics and methods*****. Springer Science & Business Media.**

Dabbs, D.J. ed., 2021. ***Diagnostic immunohistochemistry: theranostic and genomic applications*****. Elsevier Health Sciences.**

Hanahan, D. and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. ***cell*****,** ***144*****(5), pp.646-674.**

Leonard, D.G. ed., 2009. ***Molecular pathology in clinical practice: oncology*****. Springer.**

Mills, S.E., Carter, D., Greenson, J.K., Reuter, V.E. and Stoler, M.H., 2012. ***Sternberg's diagnostic surgical pathology*****. Lippincott Williams & Wilkins.**

Polak, J.M., Van Noorden, S., Polak, D.J. and Van Noorden, S., 2023. ***Introduction to immunocytochemistry*****. Garland Science.**

Roskoski Jr, R., 2020. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. ***Pharmacological research*****,** ***152*****, p.104609.**

Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A. and Olsson, I., 2015. Tissue-based map of the human proteome. ***Science*****,** ***347*****(6220), p.1260419.**

Overview of Immunohistochemistry (IHC)

Introduction to Immunohistochemistry

Immunohistochemistry (IHC) is a specialized technique used for the visual detection of antigens (proteins) within cells and tissues. By utilizing the specific binding affinity of antibodies to their respective antigens, IHC allows for precise identification and localization of proteins in biological samples. This technique exploits the principle of antibody-antigen interactions, where antibodies bind selectively to target antigens, enabling researchers and clinicians to visualize specific protein expressions within complex tissues.

By following these steps and ensuring proper sample preparation, immunohistochemistry can effectively reveal the presence and localization of specific antigens within tissue sections, providing valuable insights for both diagnostic and research purposes.

Applications of Immunohistochemistry

- Diagnostic Applications: IHC plays a critical role in the diagnosis of various diseases, particularly cancer. Abnormal cells in cancerous tumors often express specific tumor antigens that can be detected through IHC. This enables pathologists to identify and classify different types of cancers based on their antigenic profiles, guiding treatment decisions and prognostic assessments.

- Research Applications: In basic research, IHC is extensively used to map the distribution and localization of biomarkers and differentially expressed proteins across various tissue types. This helps in understanding cellular processes, disease mechanisms, and the functional roles of proteins within their native tissue context.

Sample Preparation for Immunohistochemistry

IHC can be performed on tissue samples that are either fixed and embedded in paraffin or cryopreserved (frozen). The preparation method depends on the preservation technique used:

1. **Paraffin-Embedded Tissue:**

    - Fixation: Tissues are fixed to preserve cellular morphology and structure. A common fixative is 10% neutral buffered formalin (NBF), typically used at room temperature for 24 hours. The fixative-to-tissue ratio ranges from 1:1 to 1:20.

    - Embedding: Fixed tissues are embedded in paraffin wax to provide support during sectioning.

- Deparaffinization: Before staining, paraffin must be removed from the tissue sections. This is done by immersing sections in xylene or suitable substitutes, followed by rehydration in alcohol solutions.

2. **Frozen Tissue:**

    - Fixation: For frozen sections, fixation can occur after sectioning, particularly if new antibodies are being tested. Common fixatives include acetone or NBF.

    - Sectioning: Tissue samples are sectioned using a microtome. The standard thickness is 4 μm for paraffin-embedded sections and 4-6 μm for frozen sections. Thicker sections, such as 7 μm, may provide different visual information compared to thinner sections, highlighting the importance of consistent sectioning techniques.

Sectioning and Tissue Preparation

The process of sectioning involves cutting tissue samples into thin slices using a microtome. Proper section thickness is crucial as it affects the quality and detail of the staining. For paraffin-embedded tissues, sections are typically 4 μm thick, while frozen sections range from 4 to 6 μm. Differences in section thickness can influence the visibility of certain tissue structures and antigens.

General Steps of Immunohistochemical Staining

1. Fixation: Properly fix the tissue to maintain morphology and antigenicity.

2. Antigen Retrieval: Treat sections to expose antigens that may be masked by the fixation process.

3. Primary Antibody Incubation: Incubate sections with a primary antibody specific to the target antigen.

4. Secondary Antibody Incubation: Incubate with a secondary antibody that binds to the primary antibody. This secondary antibody is often conjugated with a detectable marker, such as an enzyme or fluorophore.

Overview of Key Steps in Immunohistochemistry (IHC)

Antigen Retrieval

Antigen retrieval is a crucial step in immunohistochemistry that aims to unmask epitopes in the tissue, making them accessible for antibody binding. Epitopes, the specific binding sites for antibodies, may be masked during tissue fixation. Fixation often involves the

formation of methylene bridges or crosslinking of amino groups, which can obscure these epitopes. To reverse this masking, antigen retrieval techniques are employed.

- Heat-Induced Epitope Retrieval (HIER): The most common method for antigen retrieval involves applying heat to the tissue sections. This can be achieved through various means:
    - Microwave Oven: Using controlled microwave heating to apply heat uniformly.
    - Autoclave: Employing pressurized steam to heat the tissue sections.
    - Heating Plates: Using dry heat to warm the tissue sections.
    - Water Baths: Submerging the slides in heated buffer solutions.

For frozen sections, antigen retrieval is generally unnecessary due to the preservation method. However, if frozen sections have been fixed in acetone or neutral buffered formalin (NBF), antigen retrieval can enhance the IHC signal by improving epitope accessibility.

Blocking Non-Specific Binding

Non-specific binding of antibodies can lead to background staining, complicating the interpretation of results. Antibodies, despite their specificity, may weakly bind to non-target proteins with similar structures, causing unwanted staining. Blocking steps are implemented to reduce this non-specific binding.

- **Blocking Solutions:**
    - Normal Serum: Incubating the tissue with serum from the species in which the secondary antibody was produced can block non-specific sites.
    - Commercial Blocking Buffers: Ready-to-use solutions designed to minimize background staining.
    - Common Blocking Agents: These include non-fat dry milk, bovine serum albumin (BSA), or gelatin, which can block non-specific sites effectively.

Endogenous enzyme activity in the tissue can also cause background staining. To mitigate this, tissues can be treated with hydrogen peroxide, which inactivates endogenous peroxidases.

Sample Labeling

Once the tissue sample is prepared and blocked, the target antigens can be visualized using labeled antibodies. There are two main methods for labeling:

- Direct Labeling: The primary antibody is directly conjugated to a reporter molecule such as a fluorescent dye, metal, or enzyme.
- Indirect Labeling: This involves using a secondary antibody that binds to the primary antibody. The secondary antibody is conjugated to a reporter molecule, allowing for signal amplification.

Types of Antibodies

Antibodies used in IHC can be either polyclonal or monoclonal, each with distinct characteristics:

- **Polyclonal Antibodies:**
    - Production: Generated by immunizing animals such as guinea pigs, rabbits, mice, rats, or goats with the antigen of interest.
    - Characteristics: These antibodies are collected from the animal's serum, resulting in a mixture that recognizes multiple epitopes on the antigen. This can increase sensitivity but may also raise the risk of cross-reactivity.
- **Monoclonal Antibodies:**
    - Production: Produced by immunizing an animal and isolating a single antibody-producing B cell from the spleen. This cell is then fused with a cancer cell line, creating a hybridoma that produces antibodies specific to a single epitope.
    - Characteristics: Monoclonal antibodies are highly specific, binding to a single epitope, which enhances precision and reproducibility in IHC.

Primary and Secondary Antibodies

In immunohistochemical detection, antibodies are classified based on their role in the staining process:

- Primary Antibodies:
    - Function: Raised against the antigen of interest and directly bind to it.
    - Conjugation: Typically unconjugated (unlabeled), allowing flexibility in detection methods.

- Secondary Antibodies:
    - Function: Raised against the immunoglobulins of the primary antibody species, they bind to the primary antibody.
    - Conjugation: Often conjugated to linker molecules such as biotin, which can recruit reporter molecules, or directly bound to reporter molecules like enzymes or fluorophores, facilitating the visualization of the antigen.

Overview of Detection Methods in Immunohistochemistry (IHC)

Direct Detection Method

The direct detection method is a straightforward, one-step staining technique where a labeled antibody directly binds to the antigen in the tissue sections. This approach involves a single antibody that carries a detectable label, which directly interacts with the target antigen.

- **Advantages**:
    - Simplicity: The direct method is easy to perform because it uses only one antibody.
    - Speed: It is a rapid technique as it eliminates the need for multiple antibody incubation steps.
- **Disadvantages**:
    - Lower Sensitivity: The lack of signal amplification means that the sensitivity is lower compared to indirect methods. This makes it less effective for detecting low-abundance antigens.

Indirect Detection Method

The indirect detection method involves an unlabeled primary antibody that binds to the target antigen. A secondary antibody, which is labeled and specific to the primary antibody, is then applied. This secondary antibody must be raised against the IgG of the species in which the primary antibody was produced.

- **Advantages**:
    - Greater Sensitivity: The use of a secondary antibody allows for signal amplification because multiple secondary antibodies can bind to each primary antibody.

- Versatility: A limited number of labeled secondary antibodies can be used with various primary antibodies. For instance, a single secondary antibody raised against rabbit IgG can be used with any primary antibody raised in rabbits. This is particularly beneficial when multiple primary antibodies are involved, either due to polyclonal antibody use or the need to detect multiple antigens.

- **Disadvantages**:
    - Complexity: The indirect method is more complex and time-consuming due to the additional incubation step.

Chromogenic Immunohistochemistry

In chromogenic immunohistochemistry, a primary antibody binds to a specific antigen. A secondary antibody, conjugated to an enzyme (e.g., alkaline phosphatase or horseradish peroxidase), then binds to the primary antibody. The enzyme catalyzes a color-producing reaction when exposed to a chromogenic substrate like diaminobenzidine (DAB), resulting in a pigmented product that can be observed under a light microscope.

Reporter Molecules

Reporter molecules used in IHC vary depending on the detection method. The two most common types are chromogenic and fluorescence detection:

- **Chromogenic Detection**:
    - **Enzymes Used**: Alkaline phosphatase (AP) and horseradish peroxidase (HRP).
    - **Substrates**: Diaminobenzidine (DAB) is a commonly used chromogenic substrate that produces a brown precipitate visible under a light microscope.
- **Fluorescence Detection**:
    - **Fluorophores Used**: Fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), aminomethyl coumarin acetate (AMCA), and Cyanine5 (Cy5). Synthetic fluorochromes like Alexa Fluors are also popular.
    - **Visualization**: Fluorescence or confocal microscopes are used to detect the fluorescent signals.

Both chromogenic and fluorescent detection methods allow for densitometric analysis, providing quantitative data correlating the level of reporter signal to protein expression or localization.

Counterstains

Counterstaining is often applied after IHC staining to provide contrast and enhance tissue morphology visualization. Hematoxylin is a commonly used counterstain that highlights the nuclei, aiding in tissue orientation and examination.

Troubleshooting in Immunohistochemistry

Several issues can arise during the IHC process, affecting the quality and accuracy of staining:

- **Common Issues**:
    - **Background Staining**: Caused by non-specific binding of antibodies or endogenous enzyme activity. It can be minimized by diluting antibodies, adjusting incubation conditions, and using different detection systems.
    - **Weak or Absent Staining**: May result from inadequate fixation, low antigen levels, or poor antibody quality. Ensuring proper tissue preparation and antibody optimization is crucial.
- **Optimization Strategies**:
    - **Blocking Non-Specific Binding**: Incubate with normal serum or commercially available blocking buffers to reduce background staining.
    - **Adjusting Antibody Concentrations**: Dilute primary or secondary antibodies as needed.
    - **Changing Incubation Conditions**: Modify the time or temperature of antibody incubations.
    - **Positive and Negative Controls**: Use tissues known to express or lack the target antigen, and include a control omitting the primary antibody to check for non-specific staining.

Overview of Diagnostic IHC Markers and Their Clinical Applications

Introduction to Immunohistochemistry (IHC)

Immunohistochemistry (IHC) is a powerful immunostaining technique that allows for the selective identification and localization of antigens (proteins) within cells and tissues. By leveraging the specific binding interactions between antibodies and antigens, IHC can pinpoint the exact location of proteins within the tissue being examined. This makes it an invaluable tool not only for basic research but also for diagnostic purposes, particularly in identifying abnormal cells such as those found in cancerous tumors.

Advantages and Applications

IHC excels in demonstrating where a particular protein is located within the tissue, providing detailed spatial context. This capability is crucial in fields like neuroscience, where researchers can study protein expression within specific brain structures. Additionally, IHC is extensively used in diagnostic surgical pathology to immunophenotype tumors. For example, immunostaining for E-cadherin helps differentiate between ductal carcinoma in situ (DCIS), which stains positive, and lobular carcinoma in situ (LCIS), which does not stain positive. More recently, IHC has been instrumental in differentiating various forms of salivary gland, head, and neck carcinomas.

Challenges and Validation

One major disadvantage of IHC is that, unlike techniques such as Western blotting where staining is verified against a molecular weight ladder, it is challenging to confirm that the staining corresponds to the protein of interest in IHC. Therefore, primary antibodies used in IHC must be rigorously validated using techniques like Western blotting to ensure specificity and accuracy.

Common Diagnostic Markers

The range of IHC markers used in diagnostic surgical pathology is extensive. Clinical laboratories, particularly in tertiary hospitals, often maintain a vast repertoire of over 200 antibodies employed as diagnostic, prognostic, and predictive biomarkers. Some commonly used markers include:

- **BrdU (Bromodeoxyuridine)**: Identifies replicating cells and is used to detect tumors and in neuroscience research.
- **Cytokeratins**: Identify carcinomas but may also be expressed in some sarcomas.
- **CD15 and CD30**: Used for diagnosing Hodgkin's disease.
- **Alpha Fetoprotein (AFP)**: Used for yolk sac tumors and hepatocellular carcinoma.

- **CD117 (KIT)**: Targets gastrointestinal stromal tumors (GIST) and mast cell tumors.
- **CD10 (CALLA)**: Applied in renal cell carcinoma and acute lymphoblastic leukemia.
- **Prostate Specific Antigen (PSA)**: Specific for prostate cancer.
- **Estrogen and Progesterone Receptors (ER & PR)**: Utilized in diagnosing and prognosticating breast and gynecological tumors, and predicting response to hormone therapy.
- **CD20**: Identifies B-cell lymphomas.
- **CD3**: Identifies T-cell lymphomas.
- **PIN-4 Cocktail**: Targets p63, CK-5, CK-14, and AMACR, distinguishing prostate adenocarcinoma from benign glands.

Example of Diagnostic IHC Staining

- **PIN-4 Staining**: Involves using a cocktail of antibodies (p63, CK-5, CK-14, and AMACR) to differentiate benign glands from prostate adenocarcinoma. The adenocarcinoma cells typically lack basal epithelial cells (stained dark brown) and display red cytoplasms (stained by AMACR).

Directing Cancer Therapy

IHC plays a critical role in directing cancer therapy by assessing molecular targets within tumors to predict their responsiveness to treatment. For instance, many tumors are hormone-dependent, and the presence of hormone receptors can indicate potential responsiveness to antihormonal therapy.

- **Tamoxifen**: An antiestrogen used in treating breast cancer, which can be identified through hormone receptor detection via IHC.
- **Imatinib**: An intracellular tyrosine kinase inhibitor for chronic myelogenous leukemia and other tumors expressing tyrosine kinases, such as KIT in gastrointestinal stromal tumors, detectable by IHC.

Monoclonal Antibody Therapy

Monoclonal antibodies, due to their size, target cell surface proteins and have shown great efficacy in treating various cancers:

- **HER2/neu (Erb-B2)**: An overexpressed protein in many cancers, particularly breast cancer. Antibodies against HER2/neu (Herceptin) are FDA-approved for clinical treatment, and tests like Dako HercepTest, Leica Biosystems Oracle, and Ventana Pathway are used for detection.
- **EGFR (HER-1)**: Overexpressed in several cancers, including head and neck and colon cancers. Therapeutic antibodies like Erbitux (cetuximab) are used, with detection systems like Dako pharmDx.

Mapping Protein Expression

IHC is also utilized for more generalized protein profiling. The Human Protein Atlas provides comprehensive maps of protein expression in normal and cancerous tissues. Combining IHC with tissue microarrays enables detailed protein expression analysis across various tissue types, enhancing our understanding of disease mechanisms and potential therapeutic targets.